+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 14 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are investigating new treatments for metastatic castration-resistant prostate cancer mCRPC. This study evaluates the medicine ifinatamab deruxtecan I-DXd or MK-2400 compared to chemotherapy to see if it helps people live longer overall and without cancer progression. The trial is sponsored by Merck Sharp & Dohme LLC and focuses on men with advanced prostate cancer who have tried other therapies. Participants are randomly assigned to one of two groups. One group receives I-DXd at 12 mg per kg every three weeks through intravenous infusion, along with premedication to prevent nausea and vomiting. The other group receives docetaxel chemotherapy at 75 mgm every three weeks plus daily oral prednisone. Treatments continue until the cancer worsens, side effects are unacceptable, or treatment stops for other reasons. During the study, participants will have regular assessments to monitor overall survival and how long they live without cancer progression, up to about 36 months. Researchers will also track additional outcomes like time to subsequent therapies, response rates, pain progression, and side effects. Safety and treatment tolerability will be closely monitored throughout the trial, which may last up to six years for some participants.

Age: 18Years +MALEPhase 3
303 locations
G

Actively Recruiting

Researchers are studying advanced non-small cell lung cancer NSCLC with a specific KRAS G12C gene mutation to see if adding the drug LY3537982 olomorasib to standard anti-cancer treatments provides better outcomes than standard treatment alone. This Phase 3 trial evaluates different combinations including pembrolizumab with or without chemotherapy. The study is sponsored by Eli Lilly and Company and aims to improve first-line treatment options for people with this type of lung cancer. Participants receive LY3537982 orally along with pembrolizumab intravenously in 21-day cycles. Some groups also receive chemotherapy drugs like pemetrexed and platinum agents cisplatin or carboplatin. There are various study parts including dose optimization, safety lead-in, and randomized treatment arms comparing LY3537982 combinations to placebo with pembrolizumab, with or without chemotherapy. Treatment continues until certain discontinuation criteria are met. During the study, participants will have regular visits for assessments including tumor measurements, physical function, symptom questionnaires, and safety monitoring. Researchers will measure progression-free survival, treatment side effects, response rates, and quality of life over an estimated period of up to three years depending on individual progress. Participants will be closely monitored throughout to evaluate the effects and safety of the study drug combinations.

Age: 18Years +All GendersPhase 3
415 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of JNJ-78934804 compared to guselkumab in adults with moderately to severely active Crohns disease, a long-term and progressive intestinal condition. This Phase 3 study aims to assess how well these treatments work by measuring clinical and endoscopic remission at Week 48. The study is sponsored by Janssen Research & Development, LLC. Participants are randomly assigned to receive either JNJ-78934804 or guselkumab, both given as subcutaneous injections. Treatment starts with induction doses at Weeks 0, 4, and 8, followed by maintenance doses every 4 weeks from Week 12 onward. Those meeting rescue criteria during the study may receive additional induction doses of JNJ-78934804 at Weeks 16, 20, and 24, then continue maintenance dosing from Week 28. After completing the double-blind phase at Week 48, participants who may benefit can join a long-term extension phase. During the study, participants will undergo assessments to measure clinical remission, endoscopic remission, and other outcomes like deep remission and corticosteroid-free remission at various time points. Researchers will monitor patient-reported outcomes, adverse events, and serious adverse events for up to approximately three years. The study involves regular evaluations of disease activity and safety to understand treatment effects and participant well-being over time.

Age: 18Years +All GendersPhase 3
287 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of JNJ-78934804 compared to guselkumab in adults with moderately to severely active ulcerative colitis, a chronic condition causing inflammation and ulcers in the colon lining. This phase 3, randomized, double-blind, active-controlled study aims to assess how well these treatments work by measuring clinical remission at Week 48. Participants receive either JNJ-78934804 or guselkumab through subcutaneous injections. Both treatments begin with induction doses at Weeks 0, 4, and 8, followed by maintenance doses every 4 weeks starting at Week 12. Participants who meet rescue criteria during the study may receive additional induction doses of JNJ-78934804 at Weeks 16, 20, and 24, with maintenance continuing every 4 weeks from Week 28. Those completing the initial 48-week treatment phase and deemed to benefit may join a long-term extension phase. Throughout the study, participants undergo assessments including endoscopic evaluations, clinical remission status, symptom scores, quality of life questionnaires, and safety monitoring for adverse events up to approximately 3 years. The primary outcome is the percentage of participants achieving clinical remission at Week 48, with multiple secondary outcomes measured at various time points. This comprehensive evaluation helps understand the treatment effects and safety profile over time.

Age: 18Years +All GendersPhase 3
318 locations
S

Actively Recruiting

Researchers are evaluating whether adding sacituzumab tirumotecan to pembrolizumab after surgery improves treatment outcomes for adults with resectable non-small cell lung cancer NSCLC who did not achieve a complete response after initial therapy. The study focuses on comparing disease-free survival between participants receiving pembrolizumab alone and those receiving a combination of pembrolizumab and sacituzumab tirumotecan. The trial is a phase 3, randomized, open-label study sponsored by Merck Sharp & Dohme LLC. Participants first receive pembrolizumab combined with platinum-based doublet chemotherapy as neoadjuvant therapy before surgery. After surgery, participants who did not achieve pathological complete response are assigned to one of two groups one group receives sacituzumab tirumotecan every two weeks for up to 12 doses alongside pembrolizumab every six weeks for up to seven cycles, while the other group receives pembrolizumab monotherapy every six weeks for up to seven cycles. The neoadjuvant chemotherapy includes drugs such as cisplatin, pemetrexed, gemcitabine, carboplatin, and paclitaxel, chosen based on tumor histology. Throughout the study, participants will be monitored regularly with assessments including imaging scans to evaluate disease status and quality of life questionnaires. The primary outcome is disease-free survival assessed by blinded independent central review for up to approximately 93 months. Secondary outcomes include overall survival, lung cancer-specific survival, adverse events, and changes in physical functioning and symptoms related to lung cancer. The study duration can last up to nearly 10 years with follow-up visits to monitor health and treatment effects.

Age: 18Years +All GendersPhase 3
270 locations
I

Actively Recruiting

Researchers are evaluating a complex intervention to improve advance care planning ACP for severely ill elderly people living at home who are acutely admitted to hospital. This cluster randomized study involves twelve Norwegian geriatric hospital units and aims to enhance patient and family involvement in treatment decisions, improve quality of life, and support ethical and legal care planning. The project also explores barriers and facilitators to implementing ACP at clinical, health service, and governmental levels, including economic analyses. The intervention group receives a comprehensive support program that includes leadership commitment, training for staff, implementation teams, ACP coordinators, and practical tools such as guidelines and documentation templates. The control group receives no implementation support during the trial but will be offered the program afterward. The study period includes baseline, 9-month, and 18-month assessments for the intervention group and baseline and 18-month assessments for the control group. Participants will undergo questionnaires and interviews with patients, relatives, clinicians, and staff at multiple time points before, during, and after the implementation. Data from patient records and national health registers will be collected to assess the fidelity of ACP implementation, clinical outcomes, communication quality, and cost-effectiveness. The trial runs until December 2026 and includes various measures to evaluate the impact of the support program on ACP delivery and related outcomes.

Age: 70Years +All GendersPhase Not Applicable
12 locations
T

Actively Recruiting

Researchers are evaluating a preventive intervention called Condensed Internet-delivered Prolonged Exposure CIPE for people experiencing symptoms of post-traumatic stress disorder PTSD about one month after a traumatic event. The goal is to test the effectiveness and cost-effectiveness of CIPE when added to usual treatment provided by psychosocial crisis teams in Norwegian municipalities. This study addresses the lack of evidence-based preventive interventions available for victims after crises and disasters in Norway. Participants are randomly assigned to receive either treatment-as-usual TAU alone or TAU plus the CIPE intervention. CIPE is a therapist-supported, internet-based program consisting of four modules delivered over six weeks. Participants are encouraged to engage daily with their therapist through a secure platform and may have phone sessions. The total therapist contact is generally under 60 minutes, while participants work on intervention tasks about six hours weekly. TAU involves proactive support from interdisciplinary crisis teams following national guidelines. Throughout the one-year study period after trauma, participants undergo assessments including the PTSD Checklist for DSM-5 at 10 to 13 weeks, 6 months, and 12 months post-trauma. Other measures include depression, insomnia, grief symptoms, treatment satisfaction, and quality of life. Researchers will monitor use of specialized mental health services and cost-effectiveness. The study aims to understand how CIPE plus usual care compares to usual care alone in reducing PTSD symptoms and improving overall outcomes.

Age: 16Years - 99YearsAll GendersPhase Not Applicable
29 locations
E

Actively Recruiting

Researchers are evaluating the effects of Medisinstart, a pharmacy counseling service, among adults starting new medication for type 2 diabetes. This randomized controlled trial aims to understand how Medisinstart influences medication use and patient adherence, which is important for improving health outcomes and benefits for patients and society. The study compares Medisinstart with usual prescription dispensing without additional counseling. Participants in the intervention group receive two follow-up consultations with a pharmacist as part of Medisinstart, while the control group receives standard prescription dispensing. The study collects data through blood tests measuring HbA1c, an established indicator of blood sugar control, and questionnaires assessing medication adherence, beliefs about medicines, diabetes self-management, and treatment satisfaction at baseline, 6 months, and 12 months after starting the new medication. During the study, participants provide blood samples for HbA1c analysis and complete questionnaires to report on their medication use and diabetes management. Researchers monitor medication-related problems and patient beliefs about medicines during the follow-up consultations. The main outcomes measured include HbA1c levels at baseline, 6 months, and 12 months, with additional assessments of adherence and treatment satisfaction over the same periods. The total study duration for each participant spans one year after starting the new diabetes medication.

Age: 18Years +All GendersPhase Not Applicable
22 locations
E

Actively Recruiting

Researchers are investigating whether an additional preoperative visit using the Dialogue Support DS tool can improve patient understanding, expectations, and outcomes for adults scheduled for lumbar spine surgery due to degenerative spinal disorders such as disc herniation, spinal stenosis, or degenerative disc disease. This multicenter randomized controlled trial aims to assess if presenting personalized outcome predictions through the DS tool before surgery enhances patient information and reduces surgery cancellations. The study will also validate the DS tools accuracy using registry data and evaluate agreement among surgeons using the tool. Participants will be randomly assigned to either receive one extra preoperative study visit that includes the use of the DS tool or one extra visit without it. The DS visit, lasting 30 to 40 minutes, can be conducted in person or via video consultation 2 to 6 weeks before surgery. During this visit, the DS tools predicted outcomes for surgery are explained to patients visually and numerically. Both groups will have opportunities to ask questions about the surgery, recovery, and potential complications, but the DS tool will only be used in one group. Participants will complete questionnaires including the Oswestry Disability Index ODI and EuroQol 5-Dimension 5-Level EQ-5D-5L before the study visit and at 3 and 12 months after surgery. The study will measure differences in disability scores between groups, patient expectations, surgery cancellations, and cost-effectiveness. No additional imaging will be performed. Data analysis will include intention-to-treat and per-protocol approaches, with follow-up guided by the Norwegian Spine Registry. Overall, the study duration includes pre-surgery visits and one-year post-surgery follow-up.

Age: 18Years +All GendersPhase Not Applicable
2 locations
S

Actively Recruiting

Researchers are investigating palliative radiotherapy for patients with symptomatic pelvic soft tissue tumors from gastrointestinal, urological, or gynecological cancers. This national, randomized, open-label phase III trial aims to determine if a short-course radiotherapy schedule 1-2 fractions of 8 Gy provides symptom relief that is not worse than a longer schedule 5 fractions of 5 Gy. The study also evaluates health-related quality of life, toxicities, survival, and biomarkers related to tumor hypoxia as secondary and exploratory goals. Participants will receive either a short-course radiotherapy treatment of 8 Gy in 1-2 sessions or a longer course of 5 Gy in 5 sessions. Both schedules are delivered as palliative care to relieve symptoms such as pain, bleeding, or dysfunction in bowel, urinary, or vaginal areas. Patients will choose a main symptom to track during the study. The trial specifically excludes curative treatments and focuses on symptom control with radiation therapy. During the study, patients are monitored through patient-reported symptom intensity assessments, physician-reported toxicities up to 52 weeks, and survival evaluations over two years. Researchers will also collect quality of life data and explore biomarkers to better understand treatment effects. Participation involves regular symptom reporting and clinical follow-up, with the primary outcome measured 12 weeks after treatment.

Age: 18Years +All GendersPhase Not Applicable
11 locations

1-10 of 14

1